GO
Loading...

Allergan Inc

More

  • Oct 20- Allergan Inc shareholder Paulson& Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals, according to two people familiar with the matter. The hedge fund told Allergan CEO David Pyott that it would support a deal with Shire, the sources said.

  • Report: Paulson pushing Allergan-Shire merger     Monday, 20 Oct 2014 | 12:15 PM ET

    According to Reuters sources, Allergan shareholder John Paulson is urging the company to merge with Shire. CNBC's Dominic Chu has the details.

  • Oct 20- Valeant Pharmaceuticals International Inc said on Monday that it may raise its bid for Botox maker Allergan Inc after the Canadian company posted a better-than-expected quarterly profit. Allergan stock was up 1.7 percent at $180.45. Valeant's third-quarter results were keenly anticipated for their potential impact on Valeant's bid for Allergan,...

  • Early Glance: Medical Devices companies Monday, 20 Oct 2014 | 10:40 AM ET

    Allergan rose $3.01 or 1.7 percent, to $180.50. Baxter International Inc. rose$. 02 or percent, to $67.26. Boston Scientific Corp. rose$. 05 or. 4 percent, to $11.42.

  • Oct 20- Valeant Pharmaceuticals Inc Chief Executive Michael Pearson said in an interview with Reuters on Monday that he is confident a revised bid for Allergan Inc will be worth over $200 per share, once Valeant's stock rises and with cash added to the offer. Pearson said Valeant could make a revised offer at any time and that the company's stock has been hurt by...

  • Oct 20- Canada's Valeant Pharmaceuticals International Inc, embroiled in a bitter fight to take over Botox maker Allergan Inc, posted a better-than-expected quarterly profit, driven by demand for its skin, neuro and eye drugs. The company also raised its full-year adjusted earnings forecast to $8.22- $8.32 per share from $7.90- $8.10 per share to reflect its...

  • Valeant's bid for Allergan     Monday, 20 Oct 2014 | 7:22 AM ET

    Michael Pearson, Valeant Pharmaceuticals CEO, shares his thoughts on allegations Allergan released false and misleading information.

  • Final Glance: Medical Devices companies Friday, 17 Oct 2014 | 6:03 PM ET

    Allergan fell$. 51 or. 3 percent, to $177.49. Baxter International Inc. fell$. 94 or 1.4 percent, to $67.24. Boston Scientific Corp. fell$. 08 or. 7 percent, to $11.37.

  • Midday Glance: Medical Devices companies Friday, 17 Oct 2014 | 1:21 PM ET

    Allergan fell $2.34 or 1.3 percent, to $175.66. Baxter International Inc. fell$. 35 or. 5 percent, to $67.83. Boston Scientific Corp. fell$. 01 or. 1 percent, to $11.44.

  • Early Glance: Medical Devices companies Friday, 17 Oct 2014 | 10:39 AM ET

    Allergan fell$. 06 or percent, to $177.94. Baxter International Inc. fell$. 47 or. 7 percent, to $67.71. Boston Scientific Corp. fell$. 03 or. 3 percent, to $11.42.

  • CNBC's Scott Wapner reports investor Bill Ackman says he has new information that Allergan tried to manipulate Valeant's stock price lower with false information.

  • *AbbVie board recommends shareholders vote against deal. *AbbVie to pay Shire $1.64 bln break fee if deal collapses. LONDON, Oct 16- U.S. drugmaker AbbVie has pulled the plug on its plan to buy Dublin- based Shire, recommending shareholders vote against the planned $55 billion takeover following new U.S. tax rules.

  • Irish tax changes may cost U.S. groups billions Tuesday, 14 Oct 2014 | 11:15 AM ET

    *Brussels investigating schemes involving minimal tax. LONDON, Oct 14- Ireland's plan to close a "Double Irish" tax loophole could cost U.S. companies including Apple and Google billions of dollars, although a new break and pressure to tackle tax avoidance elsewhere means they are unlikely to decamp. Ireland has been an attractive base for U.S. multinationals for...

  • Ackman's fund Pershing dips on Amsterdam debut Monday, 13 Oct 2014 | 7:13 AM ET
    Bill Ackman

    Shares in Pershing Square, a fund run by activist investor Bill Ackman, opened down 2 percent on their Amsterdam debut on Monday.

  • Reuters Business News Schedule at 1800 GMT/4 PM ET Sunday, 12 Oct 2014 | 4:06 PM ET

    NEW YORK- For Federal Reserve officials already worried about a persistent lack of U.S. wage and price growth, one corner of the bond market may be suggesting even more reason for alarm. The Treasury Inflation Protected Securities market is suggesting price stagnation may be just around the corner. NEW YORK- U.S. regulators are asking banks for more detail on...

  • NEW YORK/ BOSTON, Oct 10- Fidelity Investments, the largest shareholder in Actavis Plc, has increased its holdings in takeover-target Allergan in recent months and would be supportive of a potential merger between the two drugmakers, according to people familiar with the matter. The additions would likely make Fidelity the No.8 shareholder in Allergan,...

  • Cramer: Activists are picking on the wrong chiefs Thursday, 9 Oct 2014 | 6:25 PM ET
    Jim Cramer on Mad Money.

    Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention

  • Midday movers: Tesla, Apple, Yelp & more Thursday, 9 Oct 2014 | 12:59 PM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Thursday's midday movers.

  • Oct 9- Botox maker Allergan Inc said on Thursday it expects to report third-quarter profit that is more than 20 percent higher than it previously anticipated, which it said bolsters its contention that an unsolicited takeover offer by Valeant Pharmaceuticals Inc undervalues the company. Allergan has criticized the company's model of growing through...

  • Oct 9- Botox maker Allergan Inc lifted its third-quarter profit estimate and said the updated forecast showed that Valeant Pharmaceuticals Inc's takeover offer undervalued the company. "Today's announced expectations for the third quarter and updated future outlook further demonstrate that there is a vast value gap between Valeant's offer and the...